Rhapsido
Novartis’ Rhapsido® (remibrutinib) FDA-Approved as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis’ Rhapsido® (remibrutinib) receives FDA approval as the first oral BTK inhibitor for chronic spontaneous urticaria (CSU). Filed in EU, Japan, and China (priority review).